HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Support For Cosmetic Allergen Labeling Has Foundation In Consumers' ‘Right To Know’

Executive Summary

Office of Cosmetics and Colors Linda Katz emphasizes FDA sees allergen labeling as a public health issue. While many allergic reactions are minor, “consumers who are extremely or exclusively sensitive to a particular ingredient should have a right to know.”

You may also be interested in...



EU To Expand Fragrance Allergen Labeling With Implications For California’s ‘Right To Know’

Companies will have more fragrance allergens to report to California health authorities if the European Union requires more than 50 additional fragrance allergens to be labeled on cosmetic products, as proposed by the Commission in September.

US FDA Cosmetics Director Lists Talc, Formaldehyde In Hair Smoothers Among Priorities

Linda Katz, director of the FDA’s Office of Cosmetics and Colors, touched on cosmetics modernization legislation in her 21 September presentation on agency priorities at the Independent Beauty Association’s virtual FDA Cosmetics Regulations Workshop.

Making Cosmetics Reform Beneficial For All; Former FDA Cosmetics Director Yearns For ‘Serious Sit-Down’

Federal legislative reform is an historic opportunity not only to strengthen the US FDA’s oversight of the cosmetics sector, but also to modernize the industry and its value proposition to consumers. John Bailey, independent advisor for cosmetics and colors at EAS Consulting Group, is confident there’s a way to do all, but "serious" stakeholder negotiations are needed.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151893

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel